ABLAVI AGOMESSOU: Open Payments
NPI 1164885778 · LAWRENCEVILLE, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,903 in 100 payments from 15 companies in 2025. Trend: 2023 $796 · 2024 $1,593 · 2025 $1,903
Food & beverage: $1,903
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 15 | $277 |
| Supernus Pharmaceuticals, Inc. | 13 | $273 |
| Alkermes, Inc. | 10 | $234 |
| Otsuka America Pharmaceutical, Inc. | 13 | $234 |
| Teva Pharmaceuticals USA, Inc. | 13 | $200 |
| Neurocrine BioSciences, Inc. | 11 | $199 |
| Lundbeck LLC | 5 | $106 |
| E.R. Squibb & Sons, L.L.C. | 5 | $105 |
| ABBVIE INC. | 4 | $104 |
| Corium, LLC | 3 | $44 |
Products named: CAPLYTA, Qelbree, ARISTADA, INGREZZA, REXULTI, ABILIFY ASIMTUFII, COBENFY, VRAYLAR.
Industry payments across GA — which companies pay providers there.
